Pfizer, Beqvez and gene therapy

Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez is a one-time therapy that was approved in the U.
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.
Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the
Pfizer says it will end global development of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia B.
Pfizer said to be discontinuing Roche-partnered hemophilia therapy Beqvez
Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has developed with Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) Spark Therapeutics for hemophilia B,

Gene therapy, childhood blindness

What a $2 million per dose gene therapy reveals about drug pricing
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Gene Therapy: Revolutionizing Medicine By Tackling Diseases At Their Genetic Roots
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Children with rare eye condition receive pioneering gene therapy in UK to preserve eyesight
Children with rare eye condition receive pioneering gene therapy in UK to preserve eyesightSource: PA The former couple ...
IFLScience on MSN1d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical Trials
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
ophthalmologytimes14h
Envision Summit 2025: Beyond the status quo in gene therapy
At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
News91d
Medical Minute: Breakthrough treatment helps children with genetic disorder regain vision
A revolutionary gene therapy treatment in London has improved the vision of children suffering from a rare genetic disorder, ...
WNEM-TV1d
Battling Bladder Cancer: New Gene Therapy to The Rescue
The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 ...